Market Cap 105.06M
Revenue (ttm) 0.00
Net Income (ttm) -140.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -18.23
Volume 1,526,500
Avg Vol 1,605,462
Day's Range N/A - N/A
Shares Out 159.18M
Stochastic %K 71%
Beta 2.32
Analysts Strong Sell
Price Target $5.03

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-t...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 902 8800
Website: fractyl.com
Address:
3 Van de Graaff Drive, Suite 200, Burlington, United States
hohumStocks
hohumStocks Aug. 19 at 1:53 PM
$GUTS Consider this... someone weighs 300 pounds and uses a GLP-1 and drops 100 pounds to achieve their target goal 200 pounds. Most people stop taking GLPs because they stop working -- because a higher dose is needed for them to continue working -- or the side effects become too much... and most people stop taking them -- this is the reality. The weight regain starts and happens usually very rapidly. - After 1 year of stopping GLPs with no intervention their weight will be back to around 250 pounds. - With Revita their weight will be slightly under 220. This is a pretty massive difference considering even 5% of weight loss can have a considerable impact on health and quality of life.
0 · Reply
Rick2058
Rick2058 Aug. 19 at 10:03 AM
$GUTS Increased position on dips, now largest holding.
0 · Reply
Merlintrader
Merlintrader Aug. 19 at 9:45 AM
$GUTS Cash of 47.1 million dollars at June 30 against 81.5 million at the start of the year, with runway guided into early 2027 and the randomised six-month REMAIN-1 pivotal readout guided to early Q4 2026. The half-year net loss of 16.3 million is flattered by a non-cash warrant gain: cash fell 34.4 million. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/fractyl-health-guts-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-149-19ago2026
0 · Reply
Paultown1
Paultown1 Aug. 19 at 2:28 AM
$GUTS Ok, let’s set the record straight here as to why NO ONE should listen to moron SHORT SPAMMER that Somewhereman is… Fractyl is NOT doing a reverse split before data in October. Why? Very simple…juts ask AI… After Sept 9th, they have 7 DAYS to file an appeal for a hearing. The hearing will then be scheduled 4-6 weeks after they file. Then, it can be anywhere from 1-4 weeks before the final decision. During ALL OF THIS TIME, they have a “stay” with their normal listing. So you will see Fractyl file the appeal on September 16th, the last possible day and get a hearing NO EARLIER than mid-October (likely late October). THE DATA WILL BE OUT BY MID-OCTOBER…and even if it’s not, there would be no hearing decision before November 1 at the very earliest. Juts ask ChatGPT for examples of this exact timeline executed by multiple other companies. These filings by Fractyl are simply normal housekeeping and they’ll need to R/S only IF AND AFTER the data is bad. END OF R/S nonsense!
1 · Reply
DollarDetective
DollarDetective Aug. 19 at 1:59 AM
$GUTS Why would anyone care if they reverse split? I am surprised that there is so much discussion here about this meaningless piece of data. It has nothing to do with what will drive or destroy value for Fractyl, which is the pivotal cohort data. Share price minimums on stock exchanges are completely arbitrary and basically a historical artifact. Doesn’t matter if you own 10 shares @ $1 or 1 share at $10, the pie stays the same size. Recent financials show that they are still burning at a perfectly acceptable rate and will last until early 2027, at which point we will already have some preliminary safety data from Rejuva as well as the 6 month pivotal Revita numbers. Those two sets of facts alone mean that any fundraising at that point will be on much better, possibly even non-dilutive or minimally dilutive terms. Again, why all the focus on meaningless noise while life-changing and interesting things are happening right before our eyes?
1 · Reply
stocksense2
stocksense2 Aug. 18 at 7:57 PM
$GUTS When is the Reverse split happening?
3 · Reply
Somewhereman
Somewhereman Aug. 18 at 7:46 PM
$GUTS The medical value here may eventually overcome the bad management practices ....but it's a question now of when to get in if you are not already. Too soon and you will likely get crushed and diluted after the R/S and share issue and too late and you will miss the potential bump from what is likely good Q4 pivotal data.
1 · Reply
BiotechButterflies
BiotechButterflies Aug. 18 at 5:24 PM
$GUTS ... let's face it.... a reverse split was priced in months ago...... and sizing our positions prior to data readout is all...
1 · Reply
hohumStocks
hohumStocks Aug. 18 at 5:21 PM
$GUTS Some quiet accumulation is happening.
1 · Reply
Jorlev
Jorlev Aug. 18 at 5:12 PM
$GUTS What's up, GUTS?
0 · Reply
Latest News on GUTS
Fractyl Health Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Fractyl Health Proxy statement: Proxy filing


Fractyl Health reports Q2 EPS (16c), consensus (14c)

2026-08-10T20:40:54.000Z - 8 days ago

Fractyl Health reports Q2 EPS (16c), consensus (14c)


Fractyl Health Earnings Call Transcript: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 8 days ago

Fractyl Health Earnings Call Transcript: Q2 2026


Fractyl Health Earnings release: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 8 days ago

Fractyl Health Earnings release: Q2 2026


Fractyl Health Quarterly report: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 8 days ago

Fractyl Health Quarterly report: Q2 2026


Fractyl Health to Participate in Upcoming Investor Events

Jul 22, 2026, 4:01 PM EDT - 27 days ago

Fractyl Health to Participate in Upcoming Investor Events


Fractyl Health Transcript: Study result

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Fractyl Health Transcript: Study result


Fractyl Health Press release: Study result

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Fractyl Health Press release: Study result


Fractyl Health Slides: Study result

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Fractyl Health Slides: Study result


Fractyl Health reports results from REMAIN-1 Midpoint Cohort

2026-07-15T10:05:54.000Z - 5 weeks ago

Fractyl Health reports results from REMAIN-1 Midpoint Cohort


Craig-Hallum bullish on Fractyl Health, initiates with a Buy

2026-07-01T13:10:37.000Z - 7 weeks ago

Craig-Hallum bullish on Fractyl Health, initiates with a Buy


Fractyl Health initiated with a Buy at Craig-Hallum

2026-07-01T11:30:11.000Z - 7 weeks ago

Fractyl Health initiated with a Buy at Craig-Hallum


Fractyl Health Transcript: AGM 2026

Jun 10, 2026, 12:00 PM EDT - 2 months ago

Fractyl Health Transcript: AGM 2026


Fractyl Health reports Q1 EPS 6c, consensus (16c)

2026-05-12T21:42:36.000Z - 3 months ago

Fractyl Health reports Q1 EPS 6c, consensus (16c)


Fractyl Health Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Earnings Call Transcript: Q1 2026


Fractyl Health Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Earnings release: Q1 2026


Fractyl Health Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Quarterly report: Q1 2026


Fractyl Health Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Fractyl Health Proxy statement: Proxy filing


Fractyl Health Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Fractyl Health Proxy statement: Proxy filing


Fractyl Health Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

Fractyl Health Earnings Call Transcript: Q4 2025


Fractyl Health Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

Fractyl Health Annual report: Q4 2025


Fractyl Health Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

Fractyl Health Earnings release: Q4 2025


Fractyl Health Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

Fractyl Health Annual report: Q4 2025


Fractyl Health completes randomization in REMAIN-1 cohort

2026-02-26T12:36:24.000Z - 6 months ago

Fractyl Health completes randomization in REMAIN-1 cohort


Biotech Alert: Searches spiking for these stocks today

2026-02-02T16:50:10.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today


Biotech Alert: Searches spiking for these stocks today

2026-01-30T16:10:26.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today


Fractyl Health price target lowered to $2 from $5 at BofA

2026-01-30T14:50:16.000Z - 7 months ago

Fractyl Health price target lowered to $2 from $5 at BofA


Fractyl Health Transcript: Study result

Jan 29, 2026, 8:00 AM EST - 7 months ago

Fractyl Health Transcript: Study result


Fractyl Health Press release: Study result

Jan 29, 2026, 8:00 AM EST - 7 months ago

Fractyl Health Press release: Study result


Fractyl Health Slides: Study result

Jan 29, 2026, 8:00 AM EST - 7 months ago

Fractyl Health Slides: Study result


Fractyl Health announces results from trial evaluating Revita

2026-01-29T12:21:38.000Z - 7 months ago

Fractyl Health announces results from trial evaluating Revita


Biotech Alert: Searches spiking for these stocks today

2026-01-27T17:16:01.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today


Fractyl Health appoints Lara Smith Weber as CFO

2026-01-06T12:10:45.000Z - 8 months ago

Fractyl Health appoints Lara Smith Weber as CFO


Fractyl Health outlines strategic outlook for 2026

2026-01-05T12:21:09.000Z - 8 months ago

Fractyl Health outlines strategic outlook for 2026


Fractyl Health management to meet virtually with Needham

2025-12-10T21:21:05.000Z - 8 months ago

Fractyl Health management to meet virtually with Needham


Biotech Alert: Searches spiking for these stocks today

2025-12-05T17:20:11.000Z - 9 months ago

Biotech Alert: Searches spiking for these stocks today

PLRZ


Fractyl Health Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Fractyl Health Earnings Call Transcript: Q3 2025


Fractyl Health Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Fractyl Health Quarterly report: Q3 2025


Fractyl Health Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Fractyl Health Earnings release: Q3 2025


Fractyl Health Transcript: Study Update

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Fractyl Health Transcript: Study Update


Fractyl Health Press release: Study Update

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Fractyl Health Press release: Study Update


Fractyl Health Slides: Study Update

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Fractyl Health Slides: Study Update


Fractyl Health Slides: Corporate Presentation

Sep 26, 2025, 7:00 AM EDT - 11 months ago

Fractyl Health Slides: Corporate Presentation


Fractyl Health Proxy statement: Proxy Filing

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing


Fractyl Health Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing


Fractyl Health Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings Call Transcript: Q2 2025


Fractyl Health Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Quarterly report: Q2 2025


Fractyl Health Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings release: Q2 2025


Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:15 PM EDT - 1 year ago

Fractyl Health Announces Proposed Public Offering


Fractyl Health Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings Call Transcript: Q1 2025


Fractyl Health Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings release: Q1 2025


Fractyl Health Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Quarterly report: Q1 2025


Fractyl Health Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing


Fractyl Health Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing


Fractyl Health Registration statement: Registration Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Registration statement: Registration Filing


Fractyl Health Earnings Call Transcript: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Earnings Call Transcript: Q4 2024


Fractyl Health Earnings release: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Earnings release: Q4 2024


Fractyl Health Annual report: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Annual report: Q4 2024


Fractyl Health Registration statement: Registration Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

Fractyl Health Registration statement: Registration Filing


Fractyl Health Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Earnings Call Transcript: Q3 2024


Fractyl Health Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Earnings release: Q3 2024


Fractyl Health Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Quarterly report: Q3 2024


hohumStocks
hohumStocks Aug. 19 at 1:53 PM
$GUTS Consider this... someone weighs 300 pounds and uses a GLP-1 and drops 100 pounds to achieve their target goal 200 pounds. Most people stop taking GLPs because they stop working -- because a higher dose is needed for them to continue working -- or the side effects become too much... and most people stop taking them -- this is the reality. The weight regain starts and happens usually very rapidly. - After 1 year of stopping GLPs with no intervention their weight will be back to around 250 pounds. - With Revita their weight will be slightly under 220. This is a pretty massive difference considering even 5% of weight loss can have a considerable impact on health and quality of life.
0 · Reply
Rick2058
Rick2058 Aug. 19 at 10:03 AM
$GUTS Increased position on dips, now largest holding.
0 · Reply
Merlintrader
Merlintrader Aug. 19 at 9:45 AM
$GUTS Cash of 47.1 million dollars at June 30 against 81.5 million at the start of the year, with runway guided into early 2027 and the randomised six-month REMAIN-1 pivotal readout guided to early Q4 2026. The half-year net loss of 16.3 million is flattered by a non-cash warrant gain: cash fell 34.4 million. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/fractyl-health-guts-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-149-19ago2026
0 · Reply
Paultown1
Paultown1 Aug. 19 at 2:28 AM
$GUTS Ok, let’s set the record straight here as to why NO ONE should listen to moron SHORT SPAMMER that Somewhereman is… Fractyl is NOT doing a reverse split before data in October. Why? Very simple…juts ask AI… After Sept 9th, they have 7 DAYS to file an appeal for a hearing. The hearing will then be scheduled 4-6 weeks after they file. Then, it can be anywhere from 1-4 weeks before the final decision. During ALL OF THIS TIME, they have a “stay” with their normal listing. So you will see Fractyl file the appeal on September 16th, the last possible day and get a hearing NO EARLIER than mid-October (likely late October). THE DATA WILL BE OUT BY MID-OCTOBER…and even if it’s not, there would be no hearing decision before November 1 at the very earliest. Juts ask ChatGPT for examples of this exact timeline executed by multiple other companies. These filings by Fractyl are simply normal housekeeping and they’ll need to R/S only IF AND AFTER the data is bad. END OF R/S nonsense!
1 · Reply
DollarDetective
DollarDetective Aug. 19 at 1:59 AM
$GUTS Why would anyone care if they reverse split? I am surprised that there is so much discussion here about this meaningless piece of data. It has nothing to do with what will drive or destroy value for Fractyl, which is the pivotal cohort data. Share price minimums on stock exchanges are completely arbitrary and basically a historical artifact. Doesn’t matter if you own 10 shares @ $1 or 1 share at $10, the pie stays the same size. Recent financials show that they are still burning at a perfectly acceptable rate and will last until early 2027, at which point we will already have some preliminary safety data from Rejuva as well as the 6 month pivotal Revita numbers. Those two sets of facts alone mean that any fundraising at that point will be on much better, possibly even non-dilutive or minimally dilutive terms. Again, why all the focus on meaningless noise while life-changing and interesting things are happening right before our eyes?
1 · Reply
stocksense2
stocksense2 Aug. 18 at 7:57 PM
$GUTS When is the Reverse split happening?
3 · Reply
Somewhereman
Somewhereman Aug. 18 at 7:46 PM
$GUTS The medical value here may eventually overcome the bad management practices ....but it's a question now of when to get in if you are not already. Too soon and you will likely get crushed and diluted after the R/S and share issue and too late and you will miss the potential bump from what is likely good Q4 pivotal data.
1 · Reply
BiotechButterflies
BiotechButterflies Aug. 18 at 5:24 PM
$GUTS ... let's face it.... a reverse split was priced in months ago...... and sizing our positions prior to data readout is all...
1 · Reply
hohumStocks
hohumStocks Aug. 18 at 5:21 PM
$GUTS Some quiet accumulation is happening.
1 · Reply
Jorlev
Jorlev Aug. 18 at 5:12 PM
$GUTS What's up, GUTS?
0 · Reply
Jstr22
Jstr22 Aug. 18 at 3:30 PM
$GUTS tiny silver edge on a really bloody bull. I’ll take anything today 😆
0 · Reply
2TrustHim
2TrustHim Aug. 18 at 3:07 PM
$GUTS Who's Got The Guts???
2 · Reply
stocktwit162
stocktwit162 Aug. 18 at 11:39 AM
$GUTS @BioRich looks like you were correct man this is most likely going to be a r/s play ! this is going to be my first one how far do we think it will drop ? i've looked at similar situations and its usually about 50% ? maybe i'll enter about after a 40% decrease
1 · Reply
Sunnibouno
Sunnibouno Aug. 18 at 9:29 AM
0 · Reply
Cheesyisi
Cheesyisi Aug. 18 at 1:49 AM
$GUTS they’ll need it above $1 also for institutional investors to buy
1 · Reply
DSAdsdsas
DSAdsdsas Aug. 18 at 12:42 AM
$GUTS What matters is not the current stock price, but the company’s fundamentals. Unless there are significant changes to the two pipelines they have, I don’t think there is much for me to worry about as a long-term investor. Ultimately, what matters is not the stock price, but whether my investment thesis has been compromised.
1 · Reply
StockMan3517
StockMan3517 Aug. 17 at 9:50 PM
$GUTS @BioRich was right. Tons of confusion on this board today, though mostly concentrated to a few individuals
1 · Reply
Somewhereman
Somewhereman Aug. 17 at 9:42 PM
$GUTS Timing here going forward will be critical (isn't always though) along with the R/S ratio chosen. R/S with a high ratio and early well before pivotal data ...will almost certainly invite shorts and result in market cap erosion. A smaller ratio and closer to the pivotal data reporting date may keep shorts at bay and limit subsquent market cap loss because there's a a credible medical asset here that can create significant value for the company if successful as shown by the data.
0 · Reply
Somewhereman
Somewhereman Aug. 17 at 8:57 PM
$GUTS One more thing to watch...the chosen R/S ratio will tell us more about why they are doing this. A lower ratio just to get the stock over $1 ...we could conclude would be for compliance primarily...a higher ratio..10 or 15 to 1 and you can bet it's to set themselves up after anticipated SP erosion and then have price be enough to make it worthwhile for an offering afterwards. Outstanding pivotal data may save your investment here despite the R/S but given they didn't reduce A/S of 300M proportionally...an offering of even 40M shares for example on top of a 10 to 1 R/S will result in existing shareholders holding a much smaller % of the company than before. Happy path here: R/S > Stock price falls accordingly> Pivotal Data is Great> Stock price responds > shares are offered> Stock price falls again. Best time to enter may be between stock tanking after R/S and pivotal data available (betting it's good) but before new offering is announced.
0 · Reply
dl42
dl42 Aug. 17 at 8:16 PM
$GUTS This happens all the time in small biotech. They have to put a vote out for R/S because they are close to being noncompliant. On 9/9 they will apply for extension and 99% chance they will get it. Nasdaq doesn’t want to delist stocks especially ones that have the largest potential catalyst in company history. So they will get 180 days to meet and if data is good it’s not a problem, if data is bad we get crushed, pretty simple. The quote below from Nik_CA is huge. That is not always listed in Proxy, so that tells us they don’t want to RS and they are going to do what they have to so they don’t have to. We will all know in “early Q4” when they release data. If Data is good and they file for DeNovo I’m hoping to see $3-4. Then I’d expect to see some dilution.
1 · Reply
Nik_CA
Nik_CA Aug. 17 at 6:28 PM
$GUTS Small probability but a plausible scenario for RS not being implemented even if it is approved. "Although our stockholders may approve the Reverse Stock Split, we will not effect the Reverse Stock Split if our Board does not deem it to be in the best interests of the Company and its stockholders. The Reverse Stock Split will take effect, if at all, after it is approved by a majority of the total votes cast on this proposal, is deemed by the Board to be in the best interests of the Company and its stockholders, and after filing the amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. "
3 · Reply
StockMan3517
StockMan3517 Aug. 17 at 6:09 PM
$GUTS In my opinion the R/S is almost completely irrelevant here. We all know dilution will be needed to commercialize Revita if data is good. The R/S changes how many shares you own, and how many shares need to be issued to raise that funding but it does not make your shares worth any more or less from an overall dollar perspective. Raising 100M at $1 (no R/S) has the same exact dilution impact as if they do a 10-1 split and raise $100M at $10. You still have the same exact slice of the pie. This is a binary stock, the R/S and dilution won’t matter if data sucks, you’ll already have lost your $. If the data is good, the dilution just eats some of your gains. If the data is phenomenal you probably won’t even notice the dilutions impact on your gains
0 · Reply